Are you sure you want to leave?
30 September 2020
In this video presentation recorded at Nephro Update Europe (NUE) 2020, Professor Jan Kielstein* addresses the clinical challenges and expanding horizons of managing secondary hyperparathyroidism (SHPT) in non-dialysis chronic kidney disease (ND-CKD) patients. A link to the full video presentation is provided at the end of this article.
The majority of patients suffering from chronic kidney disease (CKD) are affected by mineral and bone disorder (CKD–MBD).3 Disturbances in mineral metabolism caused by declining kidney function lead to the development of SHPT.4
Professor Kielstein explains that SHPT, which is characterised by excessive secretion of parathyroid hormone (PTH) and hyperplasia of the parathyroid glands,4 is a progressive disease that manifests frequently and early in patients with CKD.3 In stage 3–4 CKD, if uncontrolled, SHPT can lead to an increased risk of bone disease, fractures and cardiovascular disease, with associated morbidity (including progression to dialysis1) and mortality.2
A number of challenges for SHPT management in ND-CKD patients remain, including:
Professor Kielstein considers the different therapeutic approaches to reducing PTH, noting that few agents are licensed for use in the ND-CKD SHPT setting, and optimal management in these patients has proven controversial.
He evaluates the use of a new 25D formulation in the treatment of SHPT in ND-CKD patients, the evidence for which helps to shine a light on what the target 25D level in ND-CKD patients should be.7 Based on the evidence, Professor Kielstein concludes that “50 [ng/mL] is the new 30.”
You can watch the full presentation by Professor Kielstein on the Streamed-up website.
Footnotes and references
*Director of Medical Clinic V, Hypertension and Nephrology, at the Tertiary Care and Teaching Hospital Braunschweig; Braunschweig, Germany.
1. Schumock G et al. Curr Med Res Opin. 2008;24:3037–48.
2. Geng G et al. Osteoporos Int. 2019;30:2019–25.
3. Levin A et al. Kidney Int. 2007;71:31.
4. Cunningham J et al. Clin J Am Soc Nephrol. 2011;6:913–21.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. Kidney Int Suppl. 2017;7:1–59.
6. Ennis JL et al. J Nephrol. 2016;29:63−70.
7. Strugnell SA et al. Am J Nephrol. 2019;49:284–93.
You are viewing a website from Vifor Pharma. This material is only intended for healthcare professionals (“HCPs”) from Europe. If you are not the intended audience, please leave this website. By checking the box, you acknowledge that you are a HCP from Europe. Approval conditions for products may vary from country to country. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
I am residing in:
Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich.